| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
HIV-1 viral escape in cerebrospinal fluid of subjects on suppressive antiretroviral treatment.
|
J Infect Dis
|
2010
|
3.46
|
|
2
|
Immune activation of the central nervous system is still present after >4 years of effective highly active antiretroviral therapy.
|
J Infect Dis
|
2007
|
1.92
|
|
3
|
Cerebrospinal fluid HIV escape associated with progressive neurologic dysfunction in patients on antiretroviral therapy with well controlled plasma viral load.
|
AIDS
|
2012
|
1.60
|
|
4
|
Persistent intrathecal immune activation in HIV-1-infected individuals on antiretroviral therapy.
|
J Acquir Immune Defic Syndr
|
2008
|
1.47
|
|
5
|
Cerebrospinal fluid and neuroimaging biomarker abnormalities suggest early neurological injury in a subset of individuals during primary HIV infection.
|
J Infect Dis
|
2013
|
1.42
|
|
6
|
Cerebrospinal fluid HIV-1 infection usually responds well to antiretroviral treatment.
|
Antivir Ther
|
2005
|
1.28
|
|
7
|
Low prevalence of transmitted drug resistance in patients newly diagnosed with HIV-1 infection in Sweden 2003-2010.
|
PLoS One
|
2012
|
1.24
|
|
8
|
CSF neurofilament protein (NFL) -- a marker of active HIV-related neurodegeneration.
|
J Neurol
|
2007
|
1.22
|
|
9
|
Treatment intensification has no effect on the HIV-1 central nervous system infection in patients on suppressive antiretroviral therapy.
|
J Acquir Immune Defic Syndr
|
2010
|
1.15
|
|
10
|
Raltegravir cerebrospinal fluid concentrations in HIV-1 infection.
|
PLoS One
|
2009
|
1.08
|
|
11
|
Cerebrospinal fluid and plasma HIV-1 RNA levels and lopinavir concentrations following lopinavir/ritonavir regimen.
|
Scand J Infect Dis
|
2004
|
1.06
|
|
12
|
Darunavir concentrations in cerebrospinal fluid and blood in HIV-1-infected individuals.
|
AIDS Res Hum Retroviruses
|
2009
|
1.04
|
|
13
|
Continuing intrathecal immunoactivation despite two years of effective antiretroviral therapy against HIV-1 infection.
|
AIDS
|
2002
|
1.04
|
|
14
|
Treatment of HIV infection: Swedish recommendations 2009.
|
Scand J Infect Dis
|
2009
|
1.03
|
|
15
|
Cerebrospinal fluid Alzheimer's biomarker profiles in CNS infections.
|
J Neurol
|
2012
|
0.99
|
|
16
|
Children born to HIV-1-infected women in Sweden in 1982-2003: trends in epidemiology and vertical transmission.
|
J Acquir Immune Defic Syndr
|
2006
|
0.99
|
|
17
|
Cerebrospinal fluid viral loads reach less than 2 copies/ml in HIV-1-infected patients with effective antiretroviral therapy.
|
Antivir Ther
|
2006
|
0.97
|
|
18
|
Cerebrospinal fluid neopterin decay characteristics after initiation of antiretroviral therapy.
|
J Neuroinflammation
|
2013
|
0.95
|
|
19
|
Acute psychotic symptoms in HIV-1 infected patients are associated with increased levels of kynurenic acid in cerebrospinal fluid.
|
Brain Behav Immun
|
2006
|
0.93
|
|
20
|
Bilirubin-a potential marker of drug exposure in atazanavir-based antiretroviral therapy.
|
AAPS J
|
2011
|
0.92
|
|
21
|
Lopinavir/ritonavir, atazanavir/ritonavir, and efavirenz in antiretroviral-naïve HIV-1-infected individuals over 144 weeks: an open-label randomized controlled trial.
|
Scand J Infect Dis
|
2013
|
0.92
|
|
22
|
The relation between treatment outcome and efavirenz, atazanavir or lopinavir exposure in the NORTHIV trial of treatment-naïve HIV-1 infected patients.
|
Eur J Clin Pharmacol
|
2009
|
0.91
|
|
23
|
Antiretroviral treatment of HIV infection: Swedish recommendations 2007.
|
Scand J Infect Dis
|
2007
|
0.88
|
|
24
|
Antiretroviral drug treatment of CNS HIV-1 infection.
|
J Antimicrob Chemother
|
2011
|
0.88
|
|
25
|
Differential effects of efavirenz, lopinavir/r, and atazanavir/r on the initial viral decay rate in treatment naïve HIV-1-infected patients.
|
AIDS Res Hum Retroviruses
|
2010
|
0.87
|
|
26
|
Antiretroviral treatment of human immunodeficiency virus infection: Swedish recommendations.
|
Scand J Infect Dis
|
2003
|
0.87
|
|
27
|
Risk of HIV transmission from patients on antiretroviral therapy: a position statement from the Public Health Agency of Sweden and the Swedish Reference Group for Antiviral Therapy.
|
Scand J Infect Dis
|
2014
|
0.86
|
|
28
|
Lyme neuroborreliosis in HIV-1 positive men successfully treated with oral doxycycline: a case series and literature review.
|
J Med Case Rep
|
2011
|
0.84
|
|
29
|
Cerebrospinal fluid HIV-1 RNA, intrathecal immunoactivation, and drug concentrations after treatment with a combination of saquinavir, nelfinavir, and two nucleoside analogues: the M61022 study.
|
BMC Infect Dis
|
2006
|
0.83
|
|
30
|
Mode of coreceptor use by R5 HIV type 1 correlates with disease stage: a study of paired plasma and cerebrospinal fluid isolates.
|
AIDS Res Hum Retroviruses
|
2009
|
0.81
|
|
31
|
Normalisation of cerebrospinal fluid biomarkers parallels improvement of neurological symptoms following HAART in HIV dementia--case report.
|
BMC Infect Dis
|
2006
|
0.79
|
|
32
|
Medical resource utilization and cost of HIV-related care in the highly active antiretroviral therapy era at a University Clinic in Sweden.
|
Pharmacoeconomics
|
2010
|
0.78
|
|
33
|
Rebound of residual plasma viremia after initial decrease following addition of intravenous immunoglobulin to effective antiretroviral treatment of HIV.
|
AIDS Res Ther
|
2011
|
0.78
|
|
34
|
Prophylaxis and treatment of HIV-1 infection in pregnancy: Swedish Recommendations 2007.
|
Scand J Infect Dis
|
2008
|
0.78
|
|
35
|
Prophylaxis and treatment of HIV-1 infection in pregnancy: Swedish recommendations 2010.
|
Scand J Infect Dis
|
2011
|
0.78
|
|
36
|
Prophylaxis and treatment of HIV-1 infection in pregnancy: Swedish recommendations 2013.
|
Scand J Infect Dis
|
2014
|
0.77
|
|
37
|
Cerebrospinal fluid viral load and intrathecal immune activation in individuals infected with different HIV-1 genetic subtypes.
|
PLoS One
|
2008
|
0.77
|
|
38
|
Immediate initiation of cART is associated with lower levels of cerebrospinal fluid YKL-40, a marker of microglial activation, in HIV-1 infection.
|
AIDS
|
2016
|
0.77
|
|
39
|
Selection of drug-resistant HIV-1 during the early phase of viral decay is uncommon in treatment-naïve patients initiated on a three- or four-drug antiretroviral regimen including lamivudine.
|
J Med Virol
|
2009
|
0.77
|
|
40
|
External validation of the bilirubin-atazanavir nomogram for assessment of atazanavir plasma exposure in HIV-1-infected patients.
|
AAPS J
|
2012
|
0.77
|
|
41
|
Retroviral rebound syndrome after treatment discontinuation in a 15 year old girl with HIV attracted through mother-to-child transmission: case report.
|
AIDS Res Ther
|
2007
|
0.75
|
|
42
|
Once-daily fosamprenavir with ritonavir in the treatment of HIV infection in therapy-naïve patients.
|
Ther Clin Risk Manag
|
2008
|
0.75
|
|
43
|
A fatal case of severe immunodeficiency associated with disseminated Merulius tremellosus infection.
|
Scand J Infect Dis
|
2006
|
0.75
|
|
44
|
Non-linear mixed effects modeling of antiretroviral drug response after administration of lopinavir, atazanavir and efavirenz containing regimens to treatment-naïve HIV-1 infected patients.
|
J Pharmacokinet Pharmacodyn
|
2011
|
0.75
|
|
45
|
Cerebrospinal fluid viral load, virus isolation, and intrathecal immunoactivation in HIV type 2 infection.
|
AIDS Res Hum Retroviruses
|
2004
|
0.75
|